Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma

Ongoing clinical trials explore T cell receptor (TCR) gene therapy as a treatment option for cancer, but responses in solid tumors are hampered by the immunosuppressive microenvironment. The production of TCR gene-engineered T cells requires full T cell activation in vitro, and it is currently unkno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotblack, Alastair, Holler, Angelika, Piapi, Alice, Ward, Sophie, Stauss, Hans J., Bennett, Clare L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986719/
https://www.ncbi.nlm.nih.gov/pubmed/29628306
http://dx.doi.org/10.1016/j.ymthe.2018.03.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986719/
https://www.ncbi.nlm.nih.gov/pubmed/29628306
http://dx.doi.org/10.1016/j.ymthe.2018.03.011

Ejemplares similares